431 results on '"Diaz, Ricardo Sobhie"'
Search Results
2. T cell-mediated Immune response and correlates of inflammation and their relationship with COVID-19 clinical severity: not an intuitive guess
3. Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil
4. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
5. Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.
6. People living with HIV co‐infected with the Kaposi Sarcoma‐associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma.
7. Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294
8. Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection
9. Could well-established, widely available, and simple laboratory techniques explain a laboratory origin of SARS-CoV-2?
10. Efficient Identification of HIV Serodiscordant Couples by Existing HIV Testing Programs in South Brazil
11. Latency-associated DNA methylation patterns among HIV-1 infected individuals with distinct disease progression courses or antiretroviral virologic response
12. Serological and molecular epidemiology of the Dengue, Zika and Chikungunya viruses in a risk area in Brazil
13. EP-039 - SOROPREVALÊNCIA DE DENGUE UTILIZANDO TESTE RÁPIDO EM PESSOAS VIVENDO COM HIV/AIDS NO MUNICÍPIO DE SÃO PAULO
14. Glycolysis downregulation is a hallmark of HIV‐1 latency and sensitizes infected cells to oxidative stress
15. Prolonged Antiretroviral Therapy in Adolescents With Vertical HIV Infection Leads to Different Cytokine Profiles Depending on Viremia Persistence
16. Reducing the Immunogenicity of Pulchellin A-Chain, Ribosome-Inactivating Protein Type 2, by Computational Protein Engineering for Potential New Immunotoxins
17. High prevalence and incidence of HIV-1 in a counseling and testing center in the city of Itajaí, Brazil
18. Identification of a new hepatitis B virus recombinant D2/D3 in the city of São Paulo, Brazil
19. Dolutegravir-Associated Resistance Mutations after first-line treatment failure in Brazil
20. Environmental Changes and the Impact on the Human Infections by Dengue, Chikungunya and Zika Viruses in Northern Brazil, 2010–2019
21. A Phase III, randomized study to evaluate the immunogenicity and safety of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in HIV-positive adults
22. Effects of Carbon Nanomaterials and Aloe vera on Melanomas—Where Are We? Recent Updates
23. Detection of human feces pecovirus in newly diagnosed HIV patients in Brazil
24. Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities
25. The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically
26. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
27. Antiretroviral Drug-Resistance Mutations on the Gag Gene: Mutation Dynamics during Analytic Treatment Interruption among Individuals Experiencing Virologic Failure
28. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
29. Additional file 2 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
30. Additional file 11 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
31. Additional file 7 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
32. Additional file 6 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
33. Additional file 3 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
34. Additional file 5 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
35. Additional file 4 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
36. Additional file 9 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
37. Additional file 8 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
38. Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial
39. Influence of Hepatitis B Virus (HBV) Genotype on the Clinical Course of Disease in Patients Coinfected with HBV and Hepatitis Delta Virus
40. Study of Viral Photoinactivation by UV-C Light and Photosensitizer Using a Pseudotyped Model
41. Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities
42. COVID-19 Clinical Severity, T Cell-Mediated Immune Response, and Correlates of Inflammation: Not an Intuitive Guess
43. Comparison among the BED capture enzyme immunoassay test and AxSYM avidity index assay for determining recent HIV infection and incidence in two Voluntary Counselling and Testing Centres in Northeast Brazil
44. Antiretroviral Drug Resistance Among Patients With Human Immunodeficiency Virus Who Act as Sources or Potential Sources in Occupational Accidents Involving Healthcare Workers
45. Homogenous HIV-1 subtype B quasispecies in Brazilian men and women recently infected via heterosexual transmission
46. Low Accumulation of L90M in Protease from Subtype F HIV-1 with Resistance to Protease Inhibitors Is Caused by the L89M Polymorphism
47. Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
48. Advances and Perspectives in the Use of Carbon Nanotubes in Vaccine Development
49. Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection
50. Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.